Arlington Research Center, inc.

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)5 trials
• Psoriasis5 trials
• Hidradenitis suppurativa1 trial

Phase

• Phase 39 trials
• Phase 22 trials

Status

• Active, not recruiting6 trials
• Completed4 trials
• Terminated1 trial

Lead sponsor

• Janssen Research & Development, LLC4 trials
• Eli Lilly and Company2 trials
• Acrotech Biopharma Inc.1 trial
• Pfizer1 trial
• RAPT Therapeutics, Inc., a member of the GSK plc group of companies1 trial
• and 2 more

Running trials

• Active, not recruiting

  A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

  NCT07244263· Phase 2· Takeda· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

  NCT06611163· Phase 3· Sun Pharmaceutical Industries Limited· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

  NCT06220604· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

  NCT06095115· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

  NCT06095102· Phase 3· Janssen Research & Development, LLC· Source

Closed trials

• Completed

  A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

  NCT05372419· Phase 3· Eli Lilly and Company· Source

• Completed

  A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

  NCT05571943· Phase 3· Acrotech Biopharma Inc.· Source

• Terminated

  An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

  NCT05399368· Phase 2· RAPT Therapeutics, Inc., a member of the GSK plc group of companies· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source